Study Identifies Factors Associated With Hydroxychloroquine Retinopathy
By Elana Gotkine HealthDay Reporter
MONDAY, May 13, 2024 -- Factors associated with an increased risk for hydroxychloroquine retinopathy have been identified and include female sex, older age, and chronic kidney disease stage 3 or greater, according to a study published online May 9 in JAMA Network Open.
April M. Jorge, M.D., from Massachusetts General Hospital in Boston, and colleagues identified risk factors beyond hydroxychloroquine dose and duration of use for hydroxychloroquine retinopathy in a cohort study of 4,677 patients who initiated hydroxychloroquine, continued treatment, and underwent retinopathy screening after five years of use.
The researchers found that 125 patients developed hydroxychloroquine retinopathy within 15 years. There was an association observed for older age at time of hydroxychloroquine initiation with retinopathy risk, with adjusted hazard ratios of 2.48, 3.82, and 5.68 for those aged 45 to 54, 55 to 64, and 65 years or older, respectively, compared with those younger than 45 years. Retinopathy risk was higher among women than men, for those with chronic kidney disease stage 3 or greater, and for those with tamoxifen use (hazard ratios, 3.83, 1.95, and 3.43, respectively). Compared with non-Hispanic Whites, Asian and Black patients had a higher likelihood of pericentral retinopathy (hazard ratios, 15.02 and 5.51, respectively).
"We identified several key risk factors for incident hydroxychloroquine retinopathy in addition to hydroxychloroquine dose," the authors write. "These findings are relevant to long-term users of this important and commonly prescribed medication for patients with systemic lupus erythematosus and other rheumatic and dermatologic conditions."
One author disclosed ties to Bristol Myers Squibb and Cabaletta Bio.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.